BCR and myeloproliferative neoplasm: The overall frequency and relative distribution of additional somatic mutations in our cohort was not higher than in individual BCR::ABL1pos and JAK2 V617Fpos patients and it is difficult to attribute them to the CML clone or the MPN clone in most cases.